常染色体显性多囊肾病肾移植受者静脉血栓栓塞风险增加
本研究基于单中心UMCG队列(n=1179,393例ADPKD)和多中心STCS队列(n=4415,710例ADPKD),发现ADPKD肾移植受者静脉血栓栓塞发生率显著高于非ADPKD受者,10年累积发生率在UMCG为13.5% vs 9.6%,STCS为21.0% vs 15.1%,ADPKD为独立危险因素,部分由较高血红蛋白水平介导。
要点
- ADPKD肾移植受者静脉血栓栓塞风险显著高于非ADPKD受者。
- 风险在移植后早期(<2年)最高,ADPKD为独立危险因素。
- ADPKD受者移植后血红蛋白较高,部分介导血栓风险。
核心结论
- ADPKD肾移植受者静脉血栓栓塞风险显著高于非ADPKD受者,且为独立危险因素。
- ADPKD与静脉血栓栓塞的关联至少部分由移植后较高的血红蛋白水平驱动。
研究设计与样本
- 观察性研究,单中心UMCG队列n=1179(393例ADPKD),多中心STCS队列n=4415(710例ADPKD)。
- 主要终点为移植后首次静脉血栓栓塞或静脉血栓栓塞相关死亡的时间,采用Kaplan-Meier和Cox回归分析。
主要发现
- 静脉血栓栓塞在ADPKD受者中更常见(UMCG log-rank p=0.04,STCS p<0.001)。
- 10年累积静脉血栓栓塞发生率:UMCG ADPKD 13.5% [95% CI: 9.4, 17.5] vs 非ADPKD 9.6% [95% CI: 7.0, 12.1];STCS ADPKD 21.0% [95% CI: 17.0, 24.7] vs 非ADPKD 15.1% [95% CI: 13.5, 16.6]。
- 静脉血栓栓塞中位时间:UMCG 1.7 [0.4, 4.9]年,STCS 1.4 [0.2, 4.8]年,风险在移植后<2年最高。
- 调整静脉血栓栓塞危险因素后,ADPKD仍独立相关:UMCG HR 1.80 [95% CI: 1.21, 2.69],STCS HR 1.39 [95% CI: 1.13, 1.72]。
- ADPKD受者移植后血红蛋白水平约高7.0 ± 0.8%,尤其在男性中,且红细胞增多症风险更高;将纵向血红蛋白作为时变协变量后关联减弱。
临床怎么用
- 对ADPKD肾移植受者,尤其移植后早期(<2年),应警惕静脉血栓栓塞风险。
- 监测血红蛋白水平可能有助于识别静脉血栓栓塞高危的ADPKD受者。
局限性
- 观察性研究设计,可能存在残余混杂。
- 静脉血栓栓塞通过病历回顾识别,可能存在漏诊或错分。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Kidney transplant recipients with autosomal dominant polycystic kidney disease (ADPKD) may be at higher risk of venous thromboembolism than non-ADPKD recipients. METHODS: We conducted an observational study of adult kidney transplant recipients at a single center, the University Medical Center Groningen (UMCG; n=1179, 393 with ADPKD), and replicated key analyses in the multicenter Swiss Transplant Cohort Study (STCS; n=4415, 710 with ADPKD). The primary endpoint was time to first venous thromboembolism after transplantation or death related to venous thromboembolism (identified through medical record review), analyzed using Kaplan-Meier estimates and Cox regression. Data were pooled for subgroup analyses and to assess determinants of post-transplant venous thromboembolism risk. RESULTS: Venous thromboembolism occurred more often in ADPKD than non-ADPKD kidney transplant recipients (log-rank p=0.04 and p<0.001 for UMCG and STCS, respectively). The 10-year cumulative venous thromboembolism incidence was 13.5% [95% CI: 9.4, 17.5], versus 9.6% [95% CI: 7.0, 12.1] in ADPKD versus non-ADPKD recipients in UMCG, and 21.0% [95% CI: 17.0, 24.7] versus 15.1% [95% CI: 13.5, 16.6] in STCS. Median [Q1, Q3] time to venous thromboembolism were similar across cohorts (UMCG: 1.7 [0.4, 4.9], STCS: 1.4 [0.2, 4.8] years). Venous thromboembolism risk was highest in the early (<2 years) post-transplant period. After adjustment for venous thromboembolism risk factors, ADPKD remained independently associated with post-transplant venous thromboembolism in both cohorts (UMCG HR 1.80 [95% CI: 1.21, 2.69]; STCS HR 1.39 [95% CI: 1.13, 1.72]). The association between ADPKD and risk of venous thromboembolism was more pronounced in males. Hemoglobin levels after kidney transplantation were approximately 7.0 ± 0.8% higher in ADPKD recipients, particularly in males, with corresponding higher risks of erythrocytosis during follow-up. Incorporating longitudinal hemoglobin as a time-varying covariate attenuated the association between ADPKD and venous thromboembolism, suggesting that the association was at least partially driven by higher hemoglobin levels. CONCLUSIONS: Kidney transplant recipients were at high risk for venous thromboembolism, and those with ADPKD are at an even higher risk.
引用
- Bais T, Alnaim AA, Tegzess E, et al. Risk of Venous Thromboembolism in Kidney Transplant Recipients with Autosomal Dominant Polycystic Kidney Disease. J Am Soc Nephrol. 2026. PMID: 42931822. doi:10.1681/ASN.0000001298
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。